Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

• Jonathan Z. Li ,

  * E-mail: Jli22@partners.org

  Affiliations Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Chanson J. Brumme,

  Affiliation Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America

  ⨯
• Michael M. Lederman,

  Affiliation Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America

  ⨯
• Zabrina L. Brumme,

  Affiliations Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Simon Fraser University, Burnaby, British Columbia, Canada

  ⨯
• Hongying Wang,

  Affiliation Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• John Spritzler,

  Affiliation Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Mary Carrington,

  Affiliations Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc., NCI Frederick, Frederick, Maryland, United States of America

  ⨯
• Kathleen Medvik,

  Affiliation Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America

  ⨯
• Bruce D. Walker,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

  ⨯
• Robert T. Schooley,

  Affiliation Division of Infectious Diseases, University of California San Diego, La Jolla, California, United States of America

  ⨯
• Daniel R. Kuritzkes,

  Affiliations Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• for the AIDS Clinical Trials Group A5197 Study Team